NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134 EUR | -0.74% |
|
+2.27% | +44.23% |
| 06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 06-28 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
| Sales 2024 * | 292B 42.05B 39.06B 3,321B | Sales 2025 * | 352B 50.82B 47.21B 4,014B | Capitalization | 4,460B 643B 597B 50,799B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.04B 13.97B 1,188B | Net income 2025 * | 128B 18.45B 17.14B 1,457B | EV / Sales 2024 * | 15.4 x |
| Net Debt 2024 * | 22.58B 3.26B 3.02B 257B | Net cash position 2025 * | 5.93B 855M 794M 67.53B | EV / Sales 2025 * | 12.6 x |
| P/E ratio 2024 * |
43.3
x | P/E ratio 2025 * |
35.2
x | Employees | - |
| Yield 2024 * |
1.17% | Yield 2025 * |
1.44% | Free-Float | 70.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 week | +1.13% | ||
| 1 month | +8.50% | ||
| 3 months | +13.08% | ||
| 6 months | +42.86% | ||
| Current year | +43.16% |
1 week
131.50
140.00
1 month
121.00140.00
3 years
34.90140.00
5 years
21.10140.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/90 | |
| Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 18/03/15 |
Helge Lund
CHM | Chairman | 62 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 134 | -0.74% |
| 27/06/24 | 135 | -.--% |
| 26/06/24 | 135 | -1.46% |
| 25/06/24 | 137 | +3.79% |
| 24/06/24 | 132 | -0.38% |
Real-time BOERSE MUENCHEN, June 28, 2024 at 08:54 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 815B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +2.04% | 224B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- NOVA Stock
